Argenx delivered Q4 2025 product net sales of $1.3B and $4.2B for the full year, up 90% year over year as VYVGART demand accelerated globally. The company reported Q4 operating profit of $367M and ...

Thank you, Lisa, and thanks for joining us. The biopharmaceutical and Diagnostic Solutions segment delivered another solid ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

Stevanato Group (NYSE:STVN) executives said the company closed fiscal 2025 with “solid” results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagn ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...

The new KwikPen holds four weekly doses.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...